Hepatology and Liver Transplantation, Hospital Sírio-Libanês, São Paulo, Brazil.
Hepatology and Liver Transplantation, A. C. Camargo Cancer Center, São Paulo, Brazil.
Liver Transpl. 2020 Dec;26(12):1644-1651. doi: 10.1002/lt.25875.
Pediatric living donor liver transplantation (PLDLT) is a successful therapeutic option for children with chronic and acute liver disease. After early transplant results, many technical advancements were introduced in the field to reduce the rate of complications and improve survival. The aim of this study is to present the outcomes of 975 primary PLDLTs in 3 periods: initial practice (period 1, 29 patients, January 1995 to December 1999), second period (period 2, 331 patients, January 2000 to December 2009), and third period (period 3 [P3], 615 patients, January 2010 to September 2019). Among the technical refinements introduced in P3 are the use of hyperreduced left lateral segment grafts, abdominal wall prosthetic mesh closure, double hepatic artery anastomosis, and increased use of vascular grafts for portal vein reconstruction. The outcomes included significant reductions of hepatic artery thrombosis (HAT), early portal vein thrombosis (EPVT), and retransplantation, with better patient and graft survival in P3. Additional analyses showed that the factors independently associated with worse 90-day patient survival were HAT, EPVT, and increasing Pediatric End-Stage Liver Disease score. In conclusion, the introduction of technical refinements in P3, in addition to improvements in patient care, determined a reduction in EPVT, HAT, and retransplantation. Consequently, patient and graft survival rates increased in all time points studied.
小儿活体肝移植(PLDLT)是治疗儿童慢性和急性肝病的成功治疗选择。在早期移植结果之后,该领域引入了许多技术进步,以降低并发症发生率并提高生存率。本研究旨在介绍 975 例原发性 PLDLT 的结果,这些患者分为 3 个时期:初始实践期(第 1 期,29 例患者,1995 年 1 月至 1999 年 12 月)、第二期(第 2 期,331 例患者,2000 年 1 月至 2009 年 12 月)和第三期(第 3 期[P3],615 例患者,2010 年 1 月至 2019 年 9 月)。在 P3 中引入的技术改进包括使用超小型左外叶移植物、腹部壁假体网片闭合、双重肝动脉吻合术以及增加使用血管移植物进行门静脉重建。结果包括肝动脉血栓形成(HAT)、早期门静脉血栓形成(EPVT)和再次移植的显著减少,P3 的患者和移植物存活率更好。进一步分析表明,与 90 天患者存活率较差相关的独立因素是 HAT、EPVT 和增加的小儿终末期肝病评分。总之,P3 中技术改进的引入,加上患者护理的改善,确定了 EPVT、HAT 和再次移植的减少。因此,在所有研究的时间点,患者和移植物的存活率都有所提高。